Rural America regularly presents some of the greatest challenges to quality myeloma care and cancer care in general. Though ...

The upcoming ASH meeting arrives at a moment of unprecedented therapeutic expansion in multiple myeloma – especially within the relapsed/refractory setting, where rapidly shifting standards, earlier ...

Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A third of patients with relapsed/refractory multiple myeloma ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference. Initial findings from a phase 3 trial ...

With the 2025 American Society of Hematology (ASH) Meeting & Exposition kicking off on Saturday, December 6, in Orlando, Florida, Targeted Oncology is bringing you background on the most exciting ...

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...